Active	Status	Sponsor type	Region	Phase	Filter
6 Active 4 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Thomas, Janet L
NCT05099640 / 2021-000474-29: A Study of PTC923 in Participants With Phenylketonuria	Completed	3	157	Europe, Canada, US, RoW	PTC923, Placebo	PTC Therapeutics	Phenylketonuria	04/23	05/23
SYNPHENY-3, NCT05764239: Efficacy and Safety of SYNB1934 in Patients With PKU	Terminated	3	35	Canada, US, RoW	SYNB1934v1, Placebo	Synlogic	Phenylketonuria	03/24	03/24
NCT05166161 / 2021-000497-28: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria	Recruiting	3	200	Europe, Canada, Japan, US, RoW	PTC923, Sepiapterin	PTC Therapeutics	Phenylketonuria	04/26	04/26
NCT05222178: Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency	Terminated	1	3	US	HMI-103	Homology Medicines, Inc	Phenylketonurias, PAH Deficiency, Phenylketonuria	09/23	09/23
NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome	Available	N/A		Europe, US, RoW	Idursulfase-IT, HGT-2310, TAK-609	Takeda	Hunter Syndrome